arrow
E

Elena Maria Elli

University of Messina
H指数:31
被引数:4,200

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)

意大利前瞻性研究(ROMEI)中,IPSS中危-1风险骨髓纤维化患者接受鲁索利替尼治疗的临床结果:中期分析

2026-03-250
OAAI
Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison

与最佳可用疗法相比,在既往接受过鲁索利替尼治疗的患者中,使用莫美洛替尼的总体生存率:一项匹配调整的间接比较

2026-02-210
OAAI
Revised “iRR6” model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib

修订后的“iRR6”模型在风险分层为1级的骨髓纤维化患者中使用鲁索利替尼治疗

Cancer
IF5.1
2025-08-210
OAAI
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design

探讨真性红细胞增多症的血栓栓塞危险因素:从现有证据到PROSPERO研究设计

2025-07-180
OA
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

疾病表型显著影响慢性期骨髓纤维化患者停用鲁索利替尼后的结局

2025-03-040
OAAI
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
2025-01-200
OAAI
Characterizing Thrombotic Risk in TEMPI Syndrome: A Retrospective Case Series

TEMPI综合征血栓风险特征的评估:一项回顾性病例系列研究

BLOOD
IF23.1
2024-11-050
PRE
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study
CANCER
IF5.1
2024-07-301
OAAI
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial
2024-06-154
OAAI
Idiopathic erythrocytosis: a germline disease?
2024-01-202
OAAI
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
CANCER
IF5.1
2023-12-284
OAAI
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
2023-05-030
OAAI
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
CANCER
IF5.1
2023-03-1821
OAAI
Breakthrough infections in MPN-COVID vaccinated patients
2022-11-150
OAAI
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
2022-09-277
OAAI
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis
CANCER
IF5.1
2022-04-018
OAAI